EGFR and glioblastoma: Various studies have shown the improved cytolytic activity of NKG2D CAR-NK cells when incorporated with BiKEs, achieving over 60% lysis in HER2 breast carcinoma cells [12] and increasing glioblastoma cell killing from 11–13% to 32–43% in EGFR/HER2-targeted models [13].